Lipocine (Lipocine) Growth Rank : 0 (As of May. 21, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Lipocine Growth Rank?

Lipocine has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Lipocine Growth Rank Related Terms

Thank you for viewing the detailed overview of Lipocine's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipocine (Lipocine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108

Website

http://www.lipocine.com

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.

Executives

Mahesh V. Patel	director, officer: President and CEO	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono	director	18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos	director	C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos	officer: Chief Medical Officer	675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty	officer: Principal Accounting Officer	675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi	director	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown	officer: EVP and CFO	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill	director	50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink	director	2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass	officer: EVP and Chief Commercial Offic	3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila	officer: Chief Business Officer	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran	officer: CTO and VP RandD	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell	officer: VP Finance	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons	officer: VP Corp Business Development	837 4TH AVE, SALT LAKE CITY UT 84103